Depressed Corin Levels Indicate Early Systolic Dysfunction Before Increases of Atrial Natriuretic Peptide/B-Type

Ranjana Tripathi1, Dong Wang1, Ryan Sullivan1

  • 1From the Departments of Medicine (R.T., D.W., T.-H.M.F., I.P.G., G.L.R.) and Comparative Medicine (R.S.), University of Tennessee Health Science Center, Memphis.

Insights

Corin levels drop early in dilated cardiomyopathy, preceding heart failure (HF) progression. This decline, alongside impaired natriuretic peptide activation, may worsen HF stages.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Biochemistry

Background:

  • Dilated cardiomyopathy is a leading cause of heart failure (HF).
  • Corin enzyme activates natriuretic peptides (ANP/BNP), crucial for cardiovascular homeostasis.
  • Previous studies suggest high corin protects against HF, yet HF patients exhibit low corin.

Purpose of the Study:

  • To investigate the relationship between cardiac corin expression, natriuretic peptide levels, and HF progression in a dilated cardiomyopathy model.

Main Methods:

  • Utilized a mouse model of dilated cardiomyopathy, tracking HF progression through Stages A-D.
  • Measured cardiac gene and protein expression for corin, pro-ANP, and pro-BNP.
  • Assessed cardiac systolic function (ejection fraction) and lung water longitudinally.

Main Results:

  • Cardiac corin transcripts decreased early (Stage B HF) and remained low, correlating positively with systolic function.
  • Cardiac pro-ANP/BNP transcripts increased late (Stages C/D), with plasma levels rising only in terminal HF (Stage D).
  • A temporal dyssynchrony was observed between declining corin and rising ANP/BNP levels during HF progression.

Conclusions:

  • Corin levels decline early in experimental dilated cardiomyopathy, preceding significant natriuretic peptide elevation.
  • This early corin reduction may impair pro-natriuretic peptide activation, contributing to HF worsening.
  • Findings highlight a potential mechanism linking corin deficiency to HF progression and severity.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
742
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
421
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
846
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K